Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
193
-
Total 13F shares, excl. options
-
145M
-
Shares change
-
+11.3M
-
Total reported value, excl. options
-
$1.78B
-
Value change
-
+$106M
-
Put/Call ratio
-
0.6
-
Number of buys
-
124
-
Number of sells
-
-59
-
Price
-
$12.27
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2016
235 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2016.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 193 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 145M shares
.
Largest 10 shareholders include OppenheimerFunds, Inc. (25M shares), PRIMECAP MANAGEMENT CO/CA/ (21.4M shares), BlackRock Fund Advisors (13.8M shares), VANGUARD GROUP INC (13M shares), Camber Capital Management LLC (6M shares), Invesco Ltd. (4.44M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (4.19M shares), STATE STREET CORP (4.06M shares), BRIDGER MANAGEMENT, LLC (3.94M shares), and BlackRock Institutional Trust Company, N.A. (3.76M shares).
This table shows the top 193 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.